PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer
A Double Blind Placebo Controlled Randomized Trial of PF-804 in Patients With Incurable Stage IIIB/IV Non-Small Cell Lung Cancer After Failure of Standard Therapy for Advanced or Metastatic Disease
Sponsor: NCIC Clinical Trials Group
Listed as NCT01000025, this PHASE3 trial focuses on Lung Cancer and remains completed. Sponsored by NCIC Clinical Trials Group, it has been updated 11 times since 2009, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
11 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Sep 2023 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 6 earlier versions
-
Dec 2021 — Sep 2023 [monthly]
Completed PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE3
-
May 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Aug 2019 — May 2020 [monthly]
Completed PHASE3
-
Jun 2018 — Aug 2019 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Dec 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- NCIC Clinical Trials Group
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Abbotsford, Canada , Adelaide, Australia , Arcadia, United States , Auckland, New Zealand , Aviano, Italy , Bangkok, Thailand , Barretos, Brazil , Belo Horizonte, Brazil , Benevento, Italy , Berazategui, Argentina and 68 more locations